"Aptamer-guided therapeutics and diagnostics for metabolic syndrome: Design, delivery, and translation of...

Metabolic syndrome (MetS) is a composite cardiometabolic condition defined by visceral obesity, dyslipidemia, hypertension, and insulin resistance, and it promotes the worldwide prevalence of type 2 diabetes and atherosclerotic cardiovascular disease. Nucleic-acid aptamers have developed as programmable recognition ligands that integrate antibody-like specificity with chemical synthesis, modular functionalization, low batch variability, and usually a low immunogenicity. Their translational significance in MetS is not solely in target binding, but in the capacity to establish disease-relevant affinity, stability, and tissue selectivity by advanced SELEX, counter-selection, chemical expansion, truncation, and post-SELEX maturation. Aptamers can function as pathway modulators by inhibiting ligand-receptor interactions, retaining biased receptor conformations, or concentrating therapeutic agents in metabolically compromised tissues. This provides them particularly appealing for targets characterized by receptor recycling, cell-state identification, or inflammatory interactions, rather than by a singular static biomarker. They can serve as sensitive biosensing components in aptasensors for glucose, insulin, glycated proteins, lipids, and inflammatory markers, offering more detailed metabolic phenotyping than single-analyte assays. Recent studies on insulin receptor, PCSK9, adipocyte-, and hepatocyte-targeting aptamers illustrate how aptamers may support both disease-modifying therapy and point-of-care diagnostics in obesity, insulin resistance, MASLD, and dyslipidemia. Nevertheless, matrix-aware validation, serum stability, pharmacokinetic optimization, and proof of superiority over well-known biologics and clinical tests are still necessary for effective translation. Aptamer engineering offers a versatile and mechanistically adaptable framework for precision diagnostics along with targeted intervention in Metabolic syndrome. If these challenges be successfully overcome, aptamers may transition from sophisticated binders to clinically applicable metabolic tools.